Mechanistic studies into the drivers of chronic inflammation in PWH are ongoing and may
aid in tailoring effective therapeutic strategies that can reduce ASCVD risk in this population …

The advent of newer and better tolerated antiretroviral therapy has progressively shortened
the life expectancy gap between people living with HIV (PWH) and the general population …

Background People with human immunodeficiency virus (PWH) are at increased risk for
comorbidities, and plasma interleukin 6 (IL-6) levels are among the most robust predictors of …

People with HIV (PWH) are at increased risk for atherosclerotic cardiovascular disease
(ASCVD). Proportions of vascular homing monocytes are enriched in PWH; however, little is …

Background Alterations in gut microbiota (GMB) and host metabolites have been noted in
individuals with HIV. However, it remains unclear whether alterations in GMB and related …

Summary Background Persons with HIV (PWH) have an increased risk of cardiovascular
disease (CVD) compared to HIV-seronegative individuals (SN). Inflammation contributes to …

Background: HIV infection and antiretroviral therapy (ART) have both been linked to
dyslipidemia and increased cardiovascular disease (CVD) risk. Alterations in the …

Abstract Purpose of Review Systemic inflammation increases as a consequence of aging
(inflammaging) and contributes to age-related morbidities. Inflammation in people living with …

Malaria/HIV-1 co-infection has become a significant public health problem in the tropics
where there is geographical overlap of the two diseases. It is well described that co-infection …

Abstract Purpose of Review Human immunodeficiency virus (HIV) infection and its treatment
with antiretroviral therapy (ART) are associated with lipid abnormalities that may enhance …